CDSCO Panel Approves Updated Package Insert for Johnson and Johnson's Stelara Susmita Roy5 Nov 2025 4:51 PM ISTNew Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended approval for the updated...
JnJ seeks USFDA nod for Stelara in treatment of pediatric ulcerative colitis Ruchika Sharma1 Nov 2025 2:01 PM ISTHorsham: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
Biocon Biologics Gets Health Canada Nod for Yesintek, a Biosimilar to Stelara Farhat Nasim23 Oct 2025 1:38 PM ISTBengaluru: Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced that Health Canada has granted a Notice of Compliance (NOC) for...
JnJ seeks USFDA nod of Stelara for pediatric Crohn's disease Ruchika Sharma18 Jun 2025 11:58 AM ISTHorsham: Johnson & Johnson is seeking the U.S. Food and Drug Administration (FDA) approval for the expansion of STELARA (ustekinumab) for the...
Biocon arm gets marketing nod in UK for plaque psoriasis drug Yesintek Ruchika Sharma26 May 2025 11:37 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has...
Biocon Biologics commercial partner launches psoriatic arthritis injection in Japan Ruchika Sharma21 May 2025 12:29 PM ISTUstekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis.
Biocon Biologics secures multiple market access agreements in US for Yesintek Ruchika Sharma5 May 2025 12:50 PM ISTYESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.
Johnson and Johnson Gets CDSCO Panel nod for Additional Indication of Ustekinumab solution for injection Dr. Divya Colin4 May 2025 5:15 PM ISTNew Delhi: The Subject Expert Committee (SEC), functional under the Central Drug Standard Control Organization (CDSCO), has granted approval to...
Phase 3 study comparing Yesintek with Stelara in adult patients with chronic plaque psoriasis shows positive results: Biocon Biologics Ruchika Sharma8 March 2025 1:30 PM ISTBengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced the successful results...
Biocon Biologics unveils Yesintek biosimilar to Stelara in US Ruchika Sharma25 Feb 2025 12:31 PM ISTYESINTEK will be available in all the same formulations currently provided by Stelara.
Biocon Biologics Yesintek gets European Commission approval for plaque psoriasis, psoriatic arthritis Ruchika Sharma18 Feb 2025 3:42 PM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the European...
Biocon Biologics gets Japenese nod for Psoriasis Vulgaris injection Ustekinumab BS Ruchika Sharma7 Jan 2025 1:15 PM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the...
